跳至主要内容
临床试验/ISRCTN09143837
ISRCTN09143837已完成未知

Effects of intravenous iron in COPD

niversity of Oxford (UK)0 个研究点目标入组 48 人开始时间: 2013年6月21日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
48

研究概览

简要总结

2020 results in https://pubmed.ncbi.nlm.nih.gov/32565444/ (added 23/06/2020)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Current inclusion criteria as of 28/09/2015:
  • 1. Patients with a diagnosis of COPD, with at least mild disease (stage II – IV on GOLD criteria classification, FEV1 <80% predicted and FEV1/ FVC <70%)
  • 2. Significant smoking history (>15 pack years, where a pack year is the product of [average number of cigarettes smoked per day] and [number of years smoked for] divided by 20) or other definite cause of COPD
  • 3. Stable COPD for at least four weeks at study initiation
  • 5. Able (in the Investigators opinion) and willing to comply with all study requirements.
  • 5. Participant is willing and able to give informed consent for participation in the study.
  • 6. Male or Female, aged 18 years or above.
  • Previous inclusion criteria:
  • 1. Patients with a diagnosis of COPD, with at least mild disease (stage II - IV on GOLD criteria classification, FEV1 <80% predicted and FEV1/ FVC <70%)
  • 2. Significant smoking history (>15 pack years, where a pack year is the product of [average number of cigarettes smoked per day] and [number of years smoked for] divided by 20) or other definite cause of COPD
  • 3. Potential to have stable COPD at study initiation
  • 4. Pulmonary arterial systolic pressure measurable on echocardiogram
  • 5. Able (in the Investigators opinion) and willing to comply with all study requirements.
  • 5. Participant is willing and able to give informed consent for participation in the study.
  • 6. Male or Female, aged 18 years or above.

排除标准

  • Current exclusion criteria as of 28/09/2015:
  • The participant may not participate in the study if ANY of the following apply:
  • 1. Female participants who are pregnant, lactating, planning pregnancy during the course of the study or of childbearing potential unless using effective contraception for the duration of the study.
  • 2. Patients taking iron supplements (in the last six weeks) or who have had a blood transfusion in the last 6 months
  • 3. Iron over-load, defined as ferritin >300mcg/ L
  • 4. Hypersensitivity to previous iron infusion
  • 5. Evidence of bacteraemia
  • 6. Significant renal or liver disease (as judged by the investigator)
  • Previous exclusion criteria:
  • The participant may not participate in the study if ANY of the following apply:
  • 1. Arterial oxygen saturations <90%
  • 2. Unstable heart disease, or other contra-indication to hypoxic exposure
  • 3. Female participants who are pregnant, lactating, planning pregnancy during the course of the study or of childbearing potential unless using effective contraception for the duration of the study
  • 4. Oral iron, blood transfusion or altitude exposure within six weeks
  • 5. Iron over-load, defined as ferritin >300mcg/ L
  • 6. Hypersensitivity to previous iron infusion
  • 7. Unable to tolerate exposure to hypoxia
  • 8. Evidence of bacteraemia, such as fevers or systemic symptoms
  • 9. Significant renal or liver disease

研究者

发起方
niversity of Oxford (UK)

相似试验